For $10.8bn the pharma giant gains a promising new mechanism, and adds immunology as a future investment area.
Neither route to the stock market covered itself in glory in the recent bull market. But how do returns really stack up?
As Apexigen throws in the towel six months after listing, can any bright spots be found in the stats on Spacs?
FDA green lights picked up in the second half, but for the really impressive number look at year-five sales.
Strong mid-stage data defy doubts following rival Pfizer’s spin off.
GSK ends long-running work targeting NY-ESO-1, and that’s bad news for Adaptimmune as well as Lyell.
The developer has now struck two rich deals for the antibiotics space, a field that infrequently sees big sums change hands.